Trans No.	Acquiring	Acquired	Entities
20070928	Aktiegolaget Volvo	Ingersoll-Rand Company Limited	Blaw-Knox Construction Equipment Corporation.
20070932	Beacon Roofing Supply, Inc	North Coast Commercial Roofing Systems, Inc.	North Coast Commercial Roofing Systems, Inc.
20070940	OCM Principal Opportunities Fund IV, IL.P.	EXCO Resources, Inc	EXCO Resources, Inc.
20070944	OCM Opportunities Fund VII, L.P	EXCO Resources, Inc	EXCO Resources, Inc.
20070949	Ambassadors international, Inc	Carnival Corporation	Windstar Sail Cruises Limited.
20070950	AP Berry Holdings, LLC	Berry Plastics Group, Inc	Berry Plastics Group, Inc.
20070951	Vestar Capital Partners V, L.P	Paul Danton (Dan) Huish	Huish Detergents, Inc.
20070952	Graham Partners II, L.P	Berry Plastics Group, Inc	Berry Plastics Group, Inc.
20070953	Apollo Investment Fund VI, L.P	Berry Plastics Group, Inc	Berry Plastics Group, Inc.
20070954	Apollo Investment Fund V, L.P	Apollo Investment Fund VI, L.P	Berry Plastics Group, Inc.
20070968	Iconix Brand Group, Inc	ROCSAN Holdings, LLC	ROCAWEAR LICENSING, LLC.
20070970	John D. Baker II	Holdco	Holdco.
20070971	Monomoy Capital Partners, L.P	Global Home Products LLP, Chapter 11 debtor in possession.	Anchor Hocking CG Operating Com- pany, LLC; Anchor Hocking Oper- ating Company, LLC, Anchor Hocking Operating Company LLC.
20070974	Zurich Financial Services	Bristol West Holdings, Inc	Bristol West Holdings, Inc.
20070975	IDB Holding Corporation Ltd	Susan W. Shoval	Guard Financial Group, Inc.
20070977	LPL Investment Holdings, Inc	Pacific Mutual Holding Company	Pacific Select Group LLC.
20070982	Spire Capital Partners II, L.P	Professional Bull Riders, Inc	Professional Bull Riders, Inc.
20070984	Marathon Special Opportunity Master Fund, Ltd.	SPX Corporation	General Signal UK Ltd.
20070986	CRFRC-D Holdings, Inc	DEG Acquisitions, LLC	DEG Acquisitions, LLC.
20070991	Ares Corporate Opportunities Fund, L.P.	EXCO Resources, Inc	EXCO Resources, Inc.
20070995	JLL Partners Fund, V, L.P	Patheon Inc	Patheon Inc.

For Further Information Contact: Sandra M. Peay, Contact Representative or Renee Hallman, Contact Representative. Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H– 303, Washington, DC 20580, (202) 326– 3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 07–1646 Filed 4–3–07; 8:45 am] BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the National Coordinator for Health Information Technology; American Health Information Community Population Health and Clinical Care Connections Workgroup Meeting

ACTION: Meeting cancellation.

SUMMARY: This notice announces the cancellation of the 15th meeting of the American Health Information Community Population Health and Clinical Care Connections Workgroup [formerly Biosurvellance Workgroup] in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.)

CANCELED DATE/TIME: April 20, 2007, from 10 a.m., to 3:30 p.m. Eastern Daylight Time.

ADDRESSES: Hubert H. Humphrey Building (200 Independence Avenue, SW., Washington, DC 20201), Room 505A. Please bring photo ID for entry to a Federal building).

FOR FURTHER INFORMATION CONTACT:

http://www.hhs.gov/healthit/ahic/ population/.

Dated: March 27, 2007.

Judith Sparrow,

Director, American Health Information Community, Office of Programs and Coordination, Office of the National Coordinator for Health Information Technology.

[FR Doc. 07–1645 Filed 4–3–07; 8:45 am] BILLING CODE 4150–24–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Misconduct in Science

AGENCY: Office of the Secretary, HHS. **ACTION:** Notice.

SUMMARY: Notice is hereby given that on March 12, 2007 the Department of Health and Human Services (HHS) Debarring Official, on behalf of the Secretary of HHS, issued a final notice of debarment based on the misconduct in science findings of the U.S. Public Health Service (PHS) in the following case:

Rebecca Uzelmeier (formerly known as Rebecca Marcus), Michigan State University: Based on the report of an investigation by Michigan State University (MSU) and additional information obtained by the Office of Research Integrity (ORI) during its oversight review, ORI found that Rebecca Uzelmeier, former doctoral student, Department of Pharmacology and Toxicology, MSU, committed misconduct in science by intentionally and knowingly fabricating and falsifying data in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), granted R01 ES02520.

ORI issued a charge letter enumerating the above findings of misconduct in science. However, on October 12, 2006, Ms. Uzelmeier filed a request for a hearing under 42 CFR part 93 to dispute these findings before the U.S. Department of Health and Human Services (HHS) Departmental Appeals Board (DAB). On October 19, 2006, ORI moved to dismiss Ms. Uzelmeier's hearing request because it failed to create a genuine dispute of either material fact or law, as required under 42 CFR 93.504. On March 5, 2007, the Administrative Law Judge (ALJ) with the DAB ruled in ORI's favor and dismissed Ms. Uzelmeier's hearing request pursuant to 42 CFR 93.504(a)(2). The ALJ found that Ms. Uzelmeier's hearing request raised defenses that either were immaterial to the charges of misconduct in science or that the ALJ had no authority to grant Ms. Uzelmeier's request for relief under Part 93.

Specifically, Ms. Uzelmeier knowingly and intentionally;

• Fabricated and falsified data in her research notebook primarily by multiple instances of using data/results generated from one experiment to represent data/ results purportedly obtained from one or more entirely different experiments; and

• Fabricated and falsified data in her thesis entitled "Characterization of the Molecular Mechanism(s) Underlying the Interaction(s) between 2,3,7,8tetrachlorodibenzo-*p*-Dioxin Mediated and Interferon Gamma Mediated Signal Transduction," including falsifying and fabricating autoradiographic films, computer image files scanned from those films, numerical data reduced from those computer files, documentation of those results in her black three-ring binder, and data in associated multiple figures and projection slides.

Ms. Uzlmeier's research concerned the interaction between the environmental toxin, dioxin, and a cytokine, interferon, on cellular signaling in the immune system. The approach was to exploit dioxin, or "TCDD" (2,3,7,8-tetrachlorodibenzo-pdioxin), as a probe that suppresses the immune system to delineate a role for the aryl hydrocarbon receptor protein (AhR), which is a cytosolic receptor that can be transported to the nucleus to also act as a nuclear transcription factor. The specific aim was to determine whether the mechanism of action of a naturally occurring regulatory factor, interferon-y (IFN- γ), to antagonize the immunosuppressive actions of dioxin, was through reduced AhR signaling.

Ms. Uzelmeier's actions caused the withdrawal of a manuscript that had been submitted for publication, the withdrawal of her mentor's PHS grant application, and her dismissal from graduate school.

The following administrative actions have been implemented for a period of five (5) years, beginning on March 12, 2007:

(1) Ms. Uzelmeier has been debarred from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as "covered transactions" as defined in the debarment regulations at 2 CFR 180 and 376; and

(2) Ms. Uzelmeier is prohibited from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as consultant.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

Chris B. Pascal,

Director, Office of Research Integrity. [FR Doc. 07–1616 Filed 4–3–07; 8:45 am] BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Solicitation for Nominations for Members of the U.S. Preventive Services Task Force

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS. ACTION: Solicits nominations for new members.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) invites nominations of individuals qualified to serve as members of the U.S. Preventive Services Task Force (the Task Force).

The Task Force, a standing, independent panel of private-sector experts in prevention and primary care, is composed of members appointed to serve for four-year terms with an option for reappointment. New members are selected each year to replace (approximately) one fourth of the Task Force members, i.e., those who are completing their appointments. Individuals nominated but not appointed in previous years, as well as those newly nominated, are considered in the annual selection process.

Task Force members meet three times a year for two days in the Washington, DC area. Member duties include reviewing and preparing comments (off site) on systematic evidence reviews prior to discussing and making recommendations on preventive services, drafting final recommendation documents, and participating in workgroups on specific topics or methods. AHRQ particularly encourages nominations of women, members of minority populations, and persons with disabilities. Interested individuals can self nominate. Organizations and individuals may nominate one or more

persons qualified for membership on the Task Force.

Qualification Requirements: The mission of the Task Force is to produce evidence-based recommendations on the appropriate screening, counseling, and provision of preventive medication for asymptomatic patients seen in the primary care setting. Therefore, in order to qualify for the Task Force, an applicant or nominee MUST demonstrate the following:

1. Knowledge and experience in the critical evaluation of research published in peer reviewed literature and in the methods of evidence review;

2. Understanding and experience in the application of synthesized evidence to clinical decision-making and/or policy;

3. Expertise in disease prevention and health promotion;

4. Ability to work collaboratively with peers; and,

5. Clinical expertise in the primary health care of children and/or adults, and/or expertise in counseling and behavioral interventions for primary care patients. Some Task Force members without primary health care clinical experience may be selected based on their expertise in methodological issues such as medical decision making, clinical epidemiology, behavioral medicine, and health economics.

Strongest consideration will be given to individuals who are recognized nationally or intentionally for scientific leadership within their field of expertise. Applicants must have no substantial conflicts of interest that would impair the scientific integrity of the work of the Task Force including financial, intellectual, or other conflicts. **DATES:** All nominations submitted in writing or electronically, and received by Thursday, May 31, 2007, will be considered for appointment to the Task Force.

Nominated individuals will be selected for the Task Force on the basis of their qualifications (in particular, those that address the required qualifications, outlined above) and the current expertise needs of the Task Force. It is anticipated that 4 individuals will be invited to serve on the Task Force beginning in January, 2008. AHRQ will retain and consider for future vacancies the nominations of those not selected during this cycle.

ADDRESSES: Submit your responses either in writing or electronically to: Gloria Washington, ATTN: USPSTF Nominations, Center for Primary Care, Prevention, and Clinical Partnerships, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville,